DOCSLIB.ORG

Title 260 WAC HORSE RACING COMMISSION

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Title 260 Title 260 WAC HORSE RACING COMMISSION Chapters 260-68-030 Taking specimens—Presence of owner or representative required—Cooperation enjoined—Penalty. [Rules of 260-08 Practice and procedure. racing, § 364, filed 4/21/61.] Repealed by Order 74.1, 260-12 General rules. filed 5/22/74, effective 7/1/74. Later promulgation, see 260-13 Class A, B, and C license—Horse racing chapter 260-70 WAC. facilities. 260-68-040 Transmittal of specimens to chief chemist. [Rules of 260-14 Rules relating to commissioners and com- racing, § 365, filed 4/21/61.] Repealed by Order 74.1, filed 5/22/74, effective 7/1/74. Later promulgation, see mission employees. chapter 260-70 WAC. 260-16 Washington-bred horses. 260-68-050 Sampling medicines and drugs. [Rules of racing, § 366, 260-20 Association grounds and facilities. filed 4/21/61.] Repealed by Order 74.1, filed 5/22/74, 260-24 Association officials and employees. effective 7/1/74. Later promulgation, see chapter 260-70 WAC. 260-28 Ownerships, trainers and employees. 260-68-060 Identification of medicine prerequisite to action on 260-32 Jockeys, apprentices and agents. report. [Rules of racing, § 367, filed 4/21/61.] Repealed 260-34 Drug and alcohol testing of licensees. by Order 74.1, filed 5/22/74, effective 7/1/74. Later pro- 260-36 Licenses. mulgation, see chapter 260-70 WAC. 260-37 Live horse racing compact. 260-68-070 Containers—Seals—Saliva test, distilled water to be used. [Rules of racing, § 368, filed 4/21/61.] Repealed 260-40 Entries, starts, nominations and by Order 74.1, filed 5/22/74, effective 7/1/74. Later pro- scratches. mulgation, see chapter 260-70 WAC. 260-44 Weights and equipment. 260-68-080 Testing horses of owner or trainer under investigation. 260-48 Mutuels. [Rules of racing, § 369, filed 4/21/61.] Repealed by Order 74.1, filed 5/22/74, effective 7/1/74. Later pro- 260-49 Advance deposit wagering. mulgation, see chapter 260-70 WAC. 260-52 The race—Paddock to finish. 260-68-090 Persons permitted at testing place. [Rules of racing, § 260-56 Objections and protests. 370, filed 4/21/61.] Repealed by Order 74.1, filed 260-60 Claiming. 5/22/74, effective 7/1/74. Later promulgation, see chap- 260-64 Winnings. ter 260-70 WAC. 260-68-100 Drugs, stimulants, narcotics—Attempted use or use 260-66 Walking over. affecting racing condition—Duty to protect horse— 260-70 Equine medication program. Penalties—Denial or return of prize—Eligibility of 260-72 Communications to and from grounds. other horses. [Order 72-4, § 260-68-100, filed 6/27/72; 260-75 Satellite locations. Rules of racing, § 371, filed 4/21/61.] Repealed by Order 74.1, filed 5/22/74, effective 7/1/74. Later pro- 260-80 Prohibited practices. mulgation, see chapter 260-70 WAC. 260-84 Penalties. 260-68-110 Drugs, stimulants, narcotics—Voiding track record. [Rules of racing, § 372, filed 4/21/61.] Repealed by DISPOSITION OF CHAPTERS FORMERLY Order 74.1, filed 5/22/74, effective 7/1/74. Later pro- CODIFIED IN THIS TITLE mulgation, see chapter 260-70 WAC. 260-68-120 Drugs, stimulants, narcotics—Attempted use or use Chapter 260-42 affecting speed of horse—Penalties. [Order 72-4, § 260- POSTPONEMENTS, CANCELLATIONS AND PREFERENCES 68-120, filed 6/27/72; Rules of racing, § 373, filed 4/21/61.] Repealed by Order 74.1, filed 5/22/74, effec- 260-42-010 Postponement from day to day. [Rules of racing, § 212, tive 7/1/74. Later promulgation, see chapter 260-70 filed 4/21/61.] Repealed by 07-11-112, filed 5/18/07, WAC. effective 6/18/07. Statutory Authority: RCW 67.16.020 260-68-130 Drugs, stimulants, narcotics—Attempted use or use and 67.16.040. Later promulgation, see WAC 260-40- affecting speed of horse—Duty to protect horse— 275. Denial or return of prize—Eligibility of other horses. 260-42-020 Refunds when stake race declared off. [Rules of racing, [Rules of racing, § 374, filed 4/21/61.] Repealed by § 213, filed 4/21/61.] Repealed by 07-11-112, filed Order 74.1, filed 5/22/74, effective 7/1/74. Later pro- 5/18/07, effective 6/18/07. Statutory Authority: RCW mulgation, see chapter 260-70 WAC. 67.16.020 and 67.16.040. Later promulgation, see 260-68-140 Hypodermic instruments. [Rules of racing, § 375, filed WAC 260-40-245. 4/21/61.] Repealed by Order 74.1, filed 5/22/74, effec- 260-42-030 Public notice. [Rules of racing, § 214, filed 4/21/61.] tive 7/1/74. Later promulgation, see chapter 260-70 Repealed by 07-11-112, filed 5/18/07, effective 6/18/07. WAC. Statutory Authority: RCW 67.16.020 and 67.16.040. 260-42-040 Preferences—Preferred list. [Rules of racing, §§ 215 260-68-150 Who may administer medications—Reports. [Rules of through 219, filed 4/21/61.] Repealed by 07-11-112, racing, § 376, filed 4/21/61.] Repealed by Order 74.1, filed 5/18/07, effective 6/18/07. Statutory Authority: filed 5/22/74, effective 7/1/74. Later promulgation, see RCW 67.16.020 and 67.16.040. chapter 260-70 WAC. Chapter 260-68 Chapter 260-76 MEDICATION AND DRUGS BOOKMAKING 260-68-010 Commission may require association to set apart place 260-76-010 Hand books and foreign books prohibited. [Rules of rac- for medication and testing. [Rules of racing, § 361, filed ing, §§ 377, 378, filed 4/21/61.] Repealed by 08-05-088, 4/21/61.] Repealed by Order 74.1, filed 5/22/74, effec- filed 2/15/08, effective 3/17/08. Statutory Authority: tive 7/1/74. Later promulgation, see chapter 260-70 RCW 67.16.020 and 67.16.040. WAC. 260-76-020 Bookmakers, vagrants, fugitives, undesirable persons, 260-68-020 Horses to be sent to testing enclosure, when. [Rules of not permitted at track. [Rules of racing, § 379, filed racing, §§ 362, 363, filed 4/21/61.] Repealed by Order 4/21/61.] Repealed by 08-05-088, filed 2/15/08, effec- 74.1, filed 5/22/74, effective 7/1/74. Later promulga- tive 3/17/08. Statutory Authority: RCW 67.16.020 and tion, see chapter 260-70 WAC. 67.16.040. (2009 Ed.) [Title 260 WAC—p. 1] Chapter 260-08 Title 260 WAC: Horse Racing Commission Chapter 260-88 11/19/93, effective 12/20/93. Statutory Authority: APPEAL TO THE COMMISSION RCW 67.16.040. 260-08-110 Service of process—Service upon parties. [Regulation 260-88-010 Hearing before the commission. [Statutory Authority: RCW 67.16.020. 04-19-047, § 260-88-010, filed 08.110, effective 4/7/60.] Repealed by 93-24-015, filed 9/13/04, effective 10/14/04; 04-05-096, § 260-88-010, 11/19/93, effective 12/20/93. Statutory Authority: RCW 67.16.040. filed 2/18/04, effective 3/20/04. Statutory Authority: RCW 67.16.040. 00-07-043, § 260-88-010, filed 3/6/00, 260-08-120 Service of process—Method of service. [Regulation effective 4/6/00; 92-17-002, § 260-88-010, filed 8/5/92, 08.120, effective 4/7/60.] Repealed by 93-24-015, filed effective 9/5/92. Statutory Authority: RCW 67.16.020 11/19/93, effective 12/20/93. Statutory Authority: and 67.16.040. 82-09-016 (Order 82-03), § 260-88-010, RCW 67.16.040. filed 4/9/82; Rules of racing, § 383, filed 4/21/61.] 260-08-130 Service of process—When service complete. [Regula- Repealed by 05-05-049, filed 2/14/05, effective 3/17/05. tion 08.130, effective 4/7/60.] Repealed by 93-24-015, Statutory Authority: RCW 67.16.020 and 67.16.040. filed 11/19/93, effective 12/20/93. Statutory Authority: RCW 67.16.040. Reviser’s note: Later promulgation, see WAC 260-08-675. 260-08-140 Service of process—Filing with commission. [Regula- tion 08.140, effective 4/7/60.] Repealed by 93-24-015, filed 11/19/93, effective 12/20/93. Statutory Authority: Chapter 260-997 RCW 67.16.040. INDEX TO TITLE 260 WAC 260-08-230 Depositions and interrogatories in contested cases— (HORSE RACING COMMISSION) Right to take. [Regulation 08.230, effective 4/7/60.] 260-997 Commission's index to Title 260 WAC. [Rules of rac- Repealed by 93-24-015, filed 11/19/93, effective ing, Index, filed 1/21/64.] Repealed by 82-09-016 12/20/93. Statutory Authority: RCW 67.16.040. (Order 82-03), filed 4/19/82. Statutory Authority: 260-08-240 Depositions and interrogatories in contested cases— RCW 67.16.020 and 67.16.040. Scope. [Regulation 08.240, effective 4/7/60.] Repealed by 93-24-015, filed 11/19/93, effective 12/20/93. Statu- tory Authority: RCW 67.16.040. 260-08-250 Depositions and interrogatories in contested cases— Chapter 260-08 Chapter 260-08 WAC Officer before whom taken. [Regulation 08.250, effec- tive 4/7/60.] Repealed by 93-24-015, filed 11/19/93, PRACTICE AND PROCEDURE effective 12/20/93. Statutory Authority: RCW WAC 67.16.040. 260-08-260 Depositions and interrogatories in contested cases— 260-08-005 Horse racing commission—Composition—Duties. Authorization. [Regulation 08.260, effective 4/7/60.] 260-08-595 Role of the executive secretary. Repealed by 93-24-015, filed 11/19/93, effective 260-08-597 Funding to assist the equine industry.
Recommended publications
  • Proxymetacaine Hydrochloride Ropivacaine Hydrochloride

    Proxymetacaine Hydrochloride Ropivacaine Hydrochloride

    1870 Local Anaesthetics Preparations pore: Alcaine; Switz.: Alcaine; Turk.: Alcaine; Opticaine; USA: Ak-Taine; Alcaine; Ocu-Caine; Ophthetic; Parcaine; Venez.: Alcaine; Oftaine†; Poen- (details are given in Part 3) caina. Proprietary Preparations CH3 Multi-ingredient: Spain: Detraine. O Multi-ingredient: Canad.: Fluoracaine†; USA: Fluoracaine; Fluorocaine. N CH3 O Quinisocaine Hydrochloride (BANM, rINNM) H3C Propipocaine (rINN) O Chinisocainum Hydrochloride; Dimethisoquin Hydrochloride Propipocaína; Propipocaïne; Propipocainum; Propoxypipero- (USAN); Dimethisoquinium Chloride; Hidrocloruro de quinisocaí- NH2 caine. 3-Piperidino-4′-propoxypropiophenone. na; Quinisocaïne, Chlorhydrate de; Quinisocaini Hydrochlori- (proxymetacaine) dum. 2-(3-Butyl-1-isoquinolyloxy)-NN-dimethylethylamine hy- Пропипокаин drochloride. C17H25NO2 = 275.4. Хинизокаина Гидрохлорид CAS — 3670-68-6. NOTE. PROX is a code approved by the BP 2008 for use on single unit doses of eye drops containing proxymetacaine hydrochlo- C17H24N2O,HCl = 308.8. ride where the individual container may be too small to bear all CAS — 86-80-6 (quinisocaine); 2773-92-4 (quinisocaine the appropriate labelling information. PROXFLN is a similar hydrochloride). O code approved for eye drops containing proxymetacaine hydro- ATC — D04AB05. chloride and fluorescein sodium. ATC Vet — QD04AB05. N Pharmacopoeias. In Br. and US. BP 2008 (Proxymetacaine Hydrochloride). A white or almost H3C CH3 white, odourless or almost odourless, crystalline powder. Soluble O in water and in chloroform; very soluble in dehydrated alcohol; N practically insoluble in ether. A 1% solution in water has a pH of O CH Profile 5.7 to 6.4. Protect from light. 3 Propipocaine is a local anaesthetic (p.1850) that has been used USP 31 (Proparacaine Hydrochloride). A white to off-white, or for surface anaesthesia.
  • 8–16–01 Vol. 66 No. 159 Thursday Aug. 16, 2001 Pages 42929

    8–16–01 Vol. 66 No. 159 Thursday Aug. 16, 2001 Pages 42929

    8–16–01 Thursday Vol. 66 No. 159 Aug. 16, 2001 Pages 42929–43064 VerDate 11-MAY-2000 19:13 Aug 15, 2001 Jkt 194001 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\16AUWS.LOC pfrm11 PsN: 16AUWS 1 II Federal Register / Vol. 66, No. 159 / Thursday, August 16, 2001 The FEDERAL REGISTER is published daily, Monday through SUBSCRIPTIONS AND COPIES Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, PUBLIC Washington, DC 20408, under the Federal Register Act (44 U.S.C. Subscriptions: Ch. 15) and the regulations of the Administrative Committee of Paper or fiche 202–512–1800 the Federal Register (1 CFR Ch. I). The Superintendent of Assistance with public subscriptions 512–1806 Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. General online information 202–512–1530; 1–888–293–6498 Single copies/back copies: The Federal Register provides a uniform system for making available to the public regulations and legal notices issued by Paper or fiche 512–1800 Federal agencies. These include Presidential proclamations and Assistance with public single copies 512–1803 Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public interest. Paper or fiche 523–5243 Assistance with Federal agency subscriptions 523–5243 Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing.
  • WO 2016/140629 Al 9 September 2016 (09.09.2016) P O P C T

    WO 2016/140629 Al 9 September 2016 (09.09.2016) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/140629 Al 9 September 2016 (09.09.2016) P O P C T (51) International Patent Classification: (74) Agent: BULUT, Pinar; FarmaPatent Limited Sirketi, A61K 36/28 (2006.01) A61P 17/02 (2006.01) GMK Bulvari No:42/5, Maltepe, 06440 Ankara (TR). A61K 36/38 (2006.01) A61P 23/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 31/167 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/TR20 15/000088 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 5 March 2015 (05.03.2015) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (25) Filing Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: PHARMACTFVE ILAC SANAYI VE Tl- TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. CARET A. S. [TR/TR]; Mahmutbey Mah. Dilmenler Cad., (84) Designated States (unless otherwise indicated, for every Aslanoba Plaza No: 19 K:3, Bagcilar/istanbul (TR).
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al

    (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al

    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
  • UNIVERSITE DE NANTES Thomas Gelineau

    UNIVERSITE DE NANTES Thomas Gelineau

    UNIVERSITE DE NANTES __________ FACULTE DE MEDECINE __________ Année 2011 N° 139 THESE pour le DIPLÔME D’ÉTAT DE DOCTEUR EN MÉDECINE DES de médecine générale par Thomas Gelineau né le 29 janvier 1983 à Cholet __________ Présentée et soutenue publiquement le 06/12/2011 __________ LE RHUME DE L'ENFANT ET SON TRAITEMENT: DECISION PARTAGEE AVEC LES PARENTS D'APRES UN QUESTIONNAIRE __________ Président : Monsieur le Professeur Olivier MALARD Directeur de thèse : Madame le Professeur Jacqueline LACAILLE 1 Table des matières IIntroduction................................................................................................................ 7 IIDéfinition, état des connaissances...........................................................................8 1Le rhume.......................................................................................................................................8 APhysiopathologie............................................................................................................................. 8 aL'origine virale.................................................................................................................................... 8 bLa saisonnalité................................................................................................................................... 8 cL'âge de survenue.............................................................................................................................. 9 dLe sexe..................................................................................................................................................
  • Local Anesthetics

    Local Anesthetics

    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
  • U.S. Lotto Markets

    U.S. Lotto Markets

    U.S. Lotto Markets By Victor A. Matheson and Kent Grote January 2008 COLLEGE OF THE HOLY CROSS, DEPARTMENT OF ECONOMICS FACULTY RESEARCH SERIES, PAPER NO. 08-02* Department of Economics College of the Holy Cross Box 45A Worcester, Massachusetts 01610 (508) 793-3362 (phone) (508) 793-3710 (fax) http://www.holycross.edu/departments/economics/website *All papers in the Holy Cross Working Paper Series should be considered draft versions subject to future revision. Comments and suggestions are welcome. U.S. Lotto Markets Victor A. Matheson† and Kent Grote†† August 2008 Abstract Lotteries as sources of public funding are of particular interest because they combine elements of both public finance and gambling in an often controversial mix. Proponents of lotteries point to the popularity of such games and justify their use because of the voluntary nature of participation rather than the reliance on compulsory taxation. Whether lotteries are efficient or not can have the usual concerns related to public finance and providing support for public spending, but there are also concerns about the efficiency of the market for the lottery products as well, especially if the voluntary participants are not behaving rationally. These concerns can be addressed through an examination of the U.S. experience with lotteries as sources of government revenues. State lotteries in the U.S. are compared to those in Europe to provide context on the use of such funding and the diversity of options available to public officials. While the efficiency of lotteries in raising funds for public programs can be addressed in a number of ways, one method is to consider whether the funds that are raised are supplementing other sources of funding or substituting for them.
  • Those Restless Little Boats on the Uneasiness of Japanese Power-Boat Gamblers

    Those Restless Little Boats on the Uneasiness of Japanese Power-Boat Gamblers

    Course No. 3507/3508 Contemporary Japanese Culture and Society Lecture No. 15 Gambling ギャンブル・賭博 GAMBLING … a national obession. Gambling fascinates, because it is a dramatized model of life. As people make their way through life, they have to make countless decisions, big and small, life-changing and trivial. In gambling, those decisions are reduced to a single type – an attempt to predict the outcome of an event. Real-life decisions often have no clear outcome; few that can clearly be called right or wrong, many that fall in the grey zone where the outcome is unclear, unimportant, or unknown. Gambling decisions have a clear outcome in success or failure: it is a black and white world where the grey of everyday life is left behind. As a simplified and dramatized model of life, gambling fascinates the social scientist as well as the gambler himself. Can the decisions made by the gambler offer us a short-cut to understanding the character of the individual, and perhaps even the collective? Gambling by its nature generates concrete, quantitative data. Do people reveal their inner character through their gambling behavior, or are they different people when gambling? In this paper I will consider these issues in relation to gambling on powerboat races (kyōtei) in Japan. Part 1: Institutional framework Gambling is supposed to be illegal in Japan, under article 23 of the Penal Code, which prescribes up to three years with hard labor for any “habitual gambler,” and three months to five years with hard labor for anyone running a gambling establishment. Gambling is unambiguously defined as both immoral and illegal.
  • Japanese Publicly Managed Gaming (Sports Gambling) and Local Government

    Japanese Publicly Managed Gaming (Sports Gambling) and Local Government

    Papers on the Local Governance System and its Implementation in Selected Fields in Japan No.16 Japanese Publicly Managed Gaming (Sports Gambling) and Local Government Yoshinori ISHIKAWA Executive director, JKA Council of Local Authorities for International Relations (CLAIR) Institute for Comparative Studies in Local Governance (COSLOG) National Graduate Institute for Policy Studies (GRIPS) Except where permitted by the Copyright Law for “personal use” or “quotation” purposes, no part of this booklet may be reproduced in any form or by any means without the permission. Any quotation from this booklet requires indication of the source. Contact Council of Local Authorities for International Relations (CLAIR) (The International Information Division) Sogo Hanzomon Building 1-7 Kojimachi, Chiyoda-ku, Tokyo 102-0083 Japan TEL: 03-5213-1724 FAX: 03-5213-1742 Email: [email protected] URL: http://www.clair.or.jp/ Institute for Comparative Studies in Local Governance (COSLOG) National Graduate Institute for Policy Studies (GRIPS) 7-22-1 Roppongi, Minato-ku, Tokyo 106-8677 Japan TEL: 03-6439-6333 FAX: 03-6439-6010 Email: [email protected] URL: http://www3.grips.ac.jp/~coslog/ Foreword The Council of Local Authorities for International Relations (CLAIR) and the National Graduate Institute for Policy Studies (GRIPS) have been working since FY 2005 on a “Project on the overseas dissemination of information on the local governance system of Japan and its operation”. On the basis of the recognition that the dissemination to overseas countries of information on the Japanese local governance system and its operation was insufficient, the objective of this project was defined as the pursuit of comparative studies on local governance by means of compiling in foreign languages materials on the Japanese local governance system and its implementation as well as by accumulating literature and reference materials on local governance in Japan and foreign countries.
  • Ovid MEDLINE(R)

    Ovid MEDLINE(R)

    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil